AGC Biologics and BioConnection Partner to Offer new
End-to-End Biopharmaceutical Drug
Substance and
Drug Product
Development and
Manufacturing Offering
- Strategic partnership provides a seamless one-stop-shop for
biopharmaceutical development and manufacturing for large pharma,
mid-size biotech’s and startup developers.
- The AGC Biologics & BioConnection collaboration offers new
option for companies evaluating the potential impact of U.S.
BIOSECURE Act.
SEATTLE &
OSS – May
22, 2024AGC
Biologics, a leading global Biopharmaceutical
Contract Development and Manufacturing Organization (CDMO), and
BioConnection, a specialized contract
manufacturing organization (CMO) focusing on aseptic filling of
vials and syringes for clinical and commercial production, today
announced a new strategic partnership. The companies are partnering
to provide end- to-end biopharmaceutical development and
manufacturing capabilities for drug substance and drug product
using the development and manufacturing expertise of AGC Biologics
and the specialized aseptic filling capabilities of
BioConnection.The new partnership offers a seamless, full-service
clinical-stage development and manufacturing solution that
accelerates timelines and brings life-saving therapies to market
more efficiently. By combining world-class drug substance and drug
product services, AGC Biologics together with BioConnection now
offer one convenient “gene to vial” value chain service with a
single contract and project management team for the project
lifecycle. Further, developers will save time and resources by
avoiding long, complex processes associated with negotiating a
separate drug substance and drug product contract and be able to
conveniently plan drug filling activities for as soon as their
substance release is scheduled – all through this new offering.
New Solution
for Companies
Potentially Impacted
by U.S.
BIOSECURE Act
This new strategic partnership addresses the ongoing needs of
the industry in the wake of the proposed U.S. BIOSECURE Act. By
having a combined end-to-end solution that uses facilities in
Japan, the United States and Europe, developers now have a reliable
and secure supply of services for development, manufacturing
(including freeze-drying) and aseptic filling for their drug
product’s needs.
AGC Biologics is especially well-positioned to
support the needs of developers that may be impacted by this
legislation, as it is one of the largest CDMO networks in the world
offering single-use bioreactor technology. Developers seeking
alternatives from their current
outsourcing partner benefit from access to AGC Biologics’
single-use network utilizing the most ubiquitous bioreactor types,
enabling an easier transfer of platform processes and reduction in
process changes associated with changing outsourcing partners.
Combined Expertise
and Resources
Through this new joint offering AGC Biologics and BioConnection
are providing comprehensive solutions to meet the increasing demand
for high-quality biopharmaceutical manufacturing services, while
also continuing to offer their services independently.
AGC Biologics offers a broad range of protein-biologics services
spanning from cell line development to commercial-scale
manufacturing across its global network of facilities on three
continents, supporting drug substances for microbial and
mammalian-based systems, plasmid DNA (pDNA) and messenger RNA
(mRNA). With a proven track record of delivering innovative
biopharmaceutical solutions to clients worldwide, including
supporting more than a dozen commercial products since 2018, AGC
Biologics is renowned for its teams with deep technical and
scientific expertise at its global facilities, and a commitment to
quality, reliability, meeting product timelines and collaborating
with developers to meet their needs.
BioConnection specializes in aseptic filling of vials and
syringes, providing clients with tailored solutions for both
clinical and commercial production of either liquid or freeze-dried
products. Equipped with state-of-the-art facilities and a highly
skilled team, BioConnection isdedicated to ensuring the highest
standards of product quality and safety. Clients have valued
BioConnection since 2005 for this and for its unmatched
customer-oriented approach.
“Now more than ever global pharmaceutical companies and
developers need reliable facilities to produce and fill their drug
products, and by combining our resources with BioConnection we are
offering a new end-to-end solution for them under one contract with
AGC Biologics,” said Patricio Massera, CEO of AGC Biologics. “We
believe BioConnection has a strong acumen, and this established
partnership will enhance our biopharmaceutical manufacturing
offerings by offering drug product service for protein biologics,
allowing us to create deeper relationships with developers to help
get their products to patients in need.”
Similarly, Alexander Willemse, CEO of BioConnection, commented,
“We are excited to join forces with AGC Biologics to offer
integrated manufacturing solutions that address the complexities of
biopharmaceutical development. Together, we are well-positioned to
support our clients at every stage.”
For more information about AGC Biologics please visit
www.agcbio.com. Visit
.www.bioconnection.eu to learn more about
BioConnection.
About AGC
Biologics
AGC Biologics is a leading global biopharmaceutical Contract
Development and Manufacturing Organization (CDMO) with a strong
commitment to delivering the highest standard of service as we work
side-by-side with our clients and partners, every step of the way.
We provide world- class development and manufacture of mammalian
and microbial-based therapeutic proteins, plasmid DNA (pDNA),
messenger RNA (mRNA), viral vectors, and genetically engineered
cells.Our global network spans the U.S., Europe, and Asia, with
cGMP-compliant facilities in Seattle, Washington; Boulder and
Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany;
Milan, Italy; and Chiba, Japan. We currently employ more than 2,500
Team Members worldwide. Our commitment to continuous innovation
fosters the technical creativity to solve our clients’ most complex
challenges, including specialization in fast-track projects and
rare diseases.
AGC Biologics is a part of AGC Inc.’s Life
Science Company. The Life Science company runs ten different
facilities focused on biopharmaceuticals, advanced therapies, small
molecule active pharmaceutical ingredients, and agrochemicals.
To learn
more, visit
www.agcbio.com.
About
BioConnection
BioConnection is a specialized contract manufacturing
organization (CMO) focusing on aseptic filling and lyophilization
of vials and syringes for clinical and commercial production. With
state- of-the-art facilities, a proven successful EMA and FDA track
record and a team of experiencedprofessionals in Oss, The
Netherlands, BioConnection provides tailored solutions to meet the
unique needs of clients in the biopharmaceutical industry.
BioConnection is specialized in fill & finish and
lyophilization of small and large molecules, orphan drugs,
personalized medicine and controlled substances. Its customers
value BioConnection for its reliability. BioConnection is renowned
forits reliability, with customers appreciating the certainty of
delivery made possible by its extensive capacity. The company
combines this reliability with a personalized approach to client
relations.
Discover more
at www.bioconnection.eu.
For more info please contact:
ACG BiologicsNick McDonald, Sr. Manager Global
Marketing and CommunicationsT: +1-425-419-355E:
nmcdonald@agcbio.com
BioConnectionDennis Link: Head of Business
DevelopmentT: +31-412-846 036E:
dennis.link@bioconnection.eu